Mattoo, S. & Cherry, J. D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev.18, 326–382 (2005).
Bisgard, K. M. et al. Infant pertussis: who was the source? Pediatr. Infect. Dis. J.23, 985–989 (2004).
Haberling, D. L., Holman, R. C., Paddock, C. D. & Murphy, T. V. Infant and maternal risk factors for pertussis-related infant mortality in the United States, 1999 to 2004. Pediatr. Infect. Dis. J.28, 194–198 (2009).
Yeung, K. H. T., Duclos, P., Nelson, E. A. S. & Hutubessy, R. C. W. An update of the global burden of pertussis in children younger than 5 years: a modelling study. Lancet Infect. Dis.17, 974–980 (2017).
Chiappini, E., Stival, A., Galli, L. & de Martino, M. Pertussis re-emergence in the post-vaccination era. BMC Infect. Dis.13, 151 (2013).
Klein, N. P., Bartlett, J., Rowhani-Rahbar, A., Fireman, B. & Baxter, R. Waning protection after fifth dose of acellular pertussis vaccine in children. N. Engl. J. Med.367, 1012–1019 (2012).
Meade, B. D., Plotkin, S. A. & Locht, C. Possible options for new pertussis vaccines. J. Infect. Dis.209, S24–27 (2014).
Clark, T. A., Messonnier, N. E. & Hadler, S. C. Pertussis control: time for something new? Trends Microbiol.20, 211–213 (2012).
Stein, P. E. et al. The crystal structure of pertussis toxin. Structure2, 45–57 (1994).
Tamura, M., Nogimori, K., Yajima, M., Ase, K. & Ui, M. A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells. J. Biol. Chem.258, 6756–6761 (1983).
Hsia, J. A. et al. Amino acid-specific ADP-ribosylation. Sensitivity to hydroxylamine of [cysteine(ADP-ribose)]protein and [arginine(ADP-ribose)]protein linkages. J. Biol. Chem.260, 16187–16191 (1985).
Locht, C., Coutte, L. & Mielcarek, N. The ins and outs of pertussis toxin. FEBS J.278, 4668–4682 (2011).
Carbonetti, N. H., Artamonova, G. V., Mays, R. M. & Worthington, Z. E. V. Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis. Infect. Immun.71, 6358–6366 (2003).
Melvin, J. A., Scheller, E. V., Miller, J. F. & Cotter, P. A. Bordetella pertussis pathogenesis: current and future challenges. Nat. Rev. Microbiol.12, 274–288 (2014).
Seubert, A., D’Oro, U., Scarselli, M. & Pizza, M. Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines. Expert Rev. Vaccines13, 1191–1204 (2014).
Burnette, W. N. et al. Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope. Science242, 72–74 (1988).
Loosmore, S. M. et al. Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccine. Infect. Immun.58, 3653–3662 (1990).
Pizza, M. et al. Mutants of pertussis toxin suitable for vaccine development. Science246, 497–500 (1989).
Antoine, R., Tallett, A., van Heyningen, S. & Locht, C. Evidence for a catalytic role of glutamic acid 129 in the NAD-glycohydrolase activity of the pertussis toxin S1 subunit. J. Biol. Chem.268, 24149–24155 (1993).
Cropley, I. et al. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment. Vaccine13, 1643–1648 (1995).
Podda, A. et al. Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G. J. Exp. Med.172, 861–868 (1990).
Leroux-Roels, G. et al. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults. Hum. Vaccines Immunother.14, 45–58 (2018).
Sirivichayakul, C. et al. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults. Hum. Vaccines Immunother.13, 136–143 (2017).
Hazes, B., Boodhoo, A., Cockle, S. A. & Read, R. J. Crystal structure of the pertussis toxin-ATP complex: a molecular sensor. J. Mol. Biol.258, 661–671 (1996).
Lobban, M. D., Irons, L. I. & van Heyningen, S. Binding of NAD+ to pertussis toxin. Biochim. Biophys. Acta1078, 155–160 (1991).
Hikono, H. et al. Activation phenotype, rather than central– or effector–memory phenotype, predicts the recall efficacy of memory CD8+ T cells. J. Exp. Med.204, 1625–1636 (2007).
Fu, X. et al. Human natural killer cells expressing the memory-associated marker CD45RO from tuberculous pleurisy respond more strongly and rapidly than CD45RO− natural killer cells following stimulation with interleukin-12. Immunology134, 41–49 (2011).
White, M. J., Nielsen, C. M., McGregor, R. H. C., Riley, E. H. C. & Goodier, M. R. Differential activation of CD57-defined natural killer cell subsets during recall responses to vaccine antigens. Immunology142, 140–150 (2014).
Baldwin, A. J. & Kay, L. E. NMR spectroscopy brings invisible protein states into focus. Nat. Chem. Biol.5, 808–814 (2009).
Naganathan, A. N. Modulation of allosteric coupling by mutations: from protein dynamics and packing to altered native ensembles and function. Curr. Opin. Struct. Biol.54, 1–9 (2019).
Malito, E. et al. Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proc. Natl Acad. Sci. USA109, 5229–5234 (2012).
Ishima, R. & Torchia, D. A. Protein dynamics from NMR. Nat. Struct. Biol.7, 740–743 (2000).
Konermann, L., Pan, J. & Liu, Y.-H. Hydrogen exchange mass spectrometry for studying protein structure and dynamics. Chem. Soc. Rev.40, 1224–1234 (2011).
Yoon, S. I., Jones, B. C., Logsdon, N. J. & Walter, M. R. Same structure, different function crystal structure of the Epstein-Barr virus IL-10 bound to the soluble IL-10R1 chain. Structure13, 551–564 (2005).
Ibsen, P. H. The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine14, 359–368 (1996).
Popovych, N., Sun, S., Ebright, R. H. & Kalodimos, C. G. Dynamically driven protein allostery. Nat. Struct. Mol. Biol.13, 831–838 (2006).
Roche, J. et al. Structural, energetic, and dynamic responses of the native state ensemble of staphylococcal nuclease to cavity-creating mutations. Proteins81, 1069–1080 (2013).
Edwards, K. M. et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics96, 548–557 (1995).
Greco, D. et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med.334, 341–348 (1996).
Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D Biol. Crystallogr.67, 293–302 (2011).
Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr.66, 22–25 (2010).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr.66, 486–501 (2010).
Ausar, S. F. et al. Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines. J. Pharm. Sci.100, 431–440 (2011).
Wales, T. E., Fadgen, K. E., Gerhardt, G. C. & Engen, J. R. High-speed and high-resolution UPLC separation at zero degrees Celsius. Anal. Chem.80, 6815–6820 (2008).
Houde, D., Berkowitz, S. A. & Engen, J. R. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies. J. Pharm. Sci.100, 2071–2086 (2011).
Zhu, S. et al. Hydrogen–deuterium exchange epitope mapping reveals distinct neutralizing mechanisms for two monoclonal antibodies against diphtheria toxin. Biochemistry58, 646–656 (2019).
Bai, Y., Milne, J. S., Mayne, L. & Englander, S. W. Primary structure effects on peptide group hydrogen exchange. Proteins17, 75–86 (1993).
Masson, G. R. et al. Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments. Nat. Methods16, 595–602 (2019).
Zhang, Z. & Smith, D. L. Determination of amide hydrogen exchange by mass spectrometry: a new tool for protein structure elucidation. Protein Sci.2, 522–531 (1993).
Wales, T. E., Eggertson, M. J. & Engen, J. R. In Mass Spectrometry Data Analysis in Proteomics, Vol. 1007 (ed. Matthiesen, R.) 263–288 (Humana Press, 2013).
Hakimi, J. et al. In Vaccine Adjuvants, Vol. 1494 (ed. Fox, C. B.) 295–304 (Springer New York, 2017).
Rahman, A. H., Tordesillas, L. & Berin, M. C. Heparin reduces nonspecific eosinophil staining artifacts in mass cytometry experiments. Cytom. A89, 601–607 (2016).
Kotecha, N., Krutzik, P. O. & Irish, J. M. Web-based analysis and publication of flow cytometry experiments. Curr. Protoc. Cytom. Chapter 10, Unit 10.17 (2010).
Amir, E. D. et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat. Biotechnol.31, 545–552 (2013).